Skip to main content
Phase III+: The University is open for expanded research operations; only authorized personnel will be admitted on campus. More info here.


6:00 – 7:00 PM EDT

A donation of $500 and above automatically
registers you for the event


William E. Ford


Dr. Richard P. Lifton


Benefit Program

The Rockefeller University’s 2021 CELEBRATING SCIENCE Virtual Benefit honors Dr. Albert Bourla. During this unprecedented time in history, Dr. Bourla’s vision, creativity, and determination led Pfizer in bringing a first-of-its-kind vaccine to the world in record time. Pfizer’s ability to join a biotech’s spirit of innovation with the power and scale of a global pharmaceutical leader has saved countless lives.

CELEBRATING SCIENCE is Rockefeller’s signature annual event, bringing together trustees, friends, and benefactors to celebrate biomedical science. Proceeds from the benefit will fund groundbreaking research by Rockefeller scientists.


Dr. Albert Bourla


As Chairman and Chief Executive Officer, Albert Bourla leads Pfizer in its purpose: Breakthroughs that change patients’ lives, with a focus on driving the scientific and commercial innovation needed to have a transformational impact on human health.

During his more than 25 years at Pfizer, Albert has built a diverse and successful career, holding several senior global positions across a range of markets and disciplines. Prior to taking the reins as CEO in 2019, he served as Chief Operating Officer beginning in 2018, and was responsible for overseeing the company’s commercial strategy, manufacturing, and global product development functions.

The previous two years, Albert was Group President of Pfizer Innovative Health, which comprised the Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease, and Vaccines business groups. In addition, he created the Patient and Health Impact Group, dedicated to developing solutions for increasing patient access, demonstrating the value of Pfizer’s medicines, and ensuring broader business model innovation.

Prior to that, he served as Group President of Pfizer’s Global Vaccines, Oncology, and Consumer Healthcare business, where he was instrumental in building a strong and competitive position in oncology and expanding the company’s leadership in vaccines.

From 2010–2013, Albert was President and General Manager of Pfizer’s Established Products business, leading the development and implementation of strategies and tactics related to Pfizer’s off-patent portfolio, including legacy brands and generics.

Albert began his Pfizer career in 1993, in the Animal Health Division as Technical Director of Greece. He held positions of increasing responsibility within Animal Health across Europe, before moving to Pfizer’s New York Global Headquarters in 2001. From there, Albert went on to assume a succession of leadership roles within the Animal Health Division, including US Group Marketing Director, Vice President of Business Development and New Products Marketing, and Area President of Animal Health Europe, Africa and the Middle East. In 2009, he assumed additional responsibilities for the Asia and Pacific regions.

Albert is a Doctor of Veterinary Medicine and holds a Ph.D. in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. In 2020, he was ranked as America’s top CEO in the Pharmaceuticals sector by Institutional Investor magazine. He is on the executive committee of The Partnership for New York City, a vice president of the International Federation of Pharmaceutical Manufacturers & Associations, a director on multiple boards – Pfizer, Inc., The Pfizer Foundation, PhRMA, and Catalyst – and a Trustee of the United States Council for International Business. He is also a member of the Business Roundtable and the Business Council.